Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Weight loss commonly lands in the range of 10 to 20 percent, which almost no other approach matches
Toxicon 54(7):988997
2 Data from the largest clinical trial of GLP-1s to date (the SELECT trial of nearly 18,000 participants) showed in November 2023 that Wegovy (Novo Nordisks GLP-1 for weight loss) reduced heart attacks, strokes and deaths due to cardiovascular disease and drove a 73% reduction in the progression toward diabetes versus the control group
At these precision levels, the difference is clinically irrelevant, but it illustrates why some practitioners round their microdose protocols to numbers that align cleanly with syringe markings
Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities in the country
